UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 29, 2010

Lexicon Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 000-30111 (Commission File Number) 76-0474169 (I.R.S. Employer Identification Number)

8800 Technology Forest Place The Woodlands, Texas 77381 (Address of principal executive offices and Zip Code)

(281) 863-3000 (Registrant's telephone number, including area code)

	Check the appropriate box below if the Form 8	3-K filing is intended	to simultaneously	satisfy the filing	obligations of the	registrant under	any of the
following	g provisions:						

]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders

Our annual meeting of stockholders was held on April 29, 2010 to consider and vote on the following proposals. The votes cast for, against or withheld, as well as the number of abstentions and broker non-votes, with respect to each matter are set forth below:

(1) Election of Class I Directors:

	Name of Director	<u>For</u>	Withheld	<u>Bı</u>	oker Non-Votes	
	Raymond Debbane	105,967,853	23,626,011		21,740,115	
	Robert J. Lefkowitz, M.D.	114,124,531	15,469,333		21,740,115	
	Alan S. Nies, M.D.	114,123,178	15,470,686		21,740,115	
(2)	Ratification and approval of the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2010	<u>For</u> 150,312,498	Against 992,120	Abstain 29,361	Broker Non- Votes —	

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Lexicon Pharmaceuticals, Inc.

Date: April 29, 2010 By: /s/ Jeffrey L. Wade

Jeffrey L. Wade Executive Vice President and General Counsel